Form 4: Assembly Biosciences Director Anthony E. Altig Acquires Stock Options

Director Anthony E. Altig acquired 2,750 stock options in Assembly Biosciences, Inc. on May 29, 2024.

Summary

• On May 29, 2024, Anthony E. Altig, a director of Assembly Biosciences, Inc., acquired 2,750 stock options.
• The exercise price of these options is $15.06.
• The options vest on the earlier of May 29, 2025, or the date of the Issuer's 2025 annual meeting of stockholders, assuming continuous service.
• The expiration date for these options is May 29, 2034.
• Following the transaction, Altig directly owns 2,750 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock option grants, which is a common practice. The director's acquisition of options can be seen as a slightly positive sign, indicating confidence in the company's future.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be an indicator of management's view of the company's prospects.

Stakeholder Impact

• The acquisition of stock options by a director can positively influence shareholder sentiment.

Key Dates